


 Cite this: *RSC Adv.*, 2021, 11, 9426

# Total synthesis of landomycins Q and R and related core structures for exploration of the cytotoxicity and antibacterial properties†

 Yao-Hsuan Lai,<sup>‡a</sup> Soumik Mondal,<sup>‡ab</sup> Hsin-Tzu Su,<sup>ab</sup> Sheng-Cih Huang,<sup>ab</sup> Mine-Hsine Wu,<sup>c</sup> I.-Wen Huang,<sup>c</sup> Tsai-Ling Yang Lauderdale,<sup>c</sup> Jen-Shin Song,<sup>c</sup> Kak-Shan Shia<sup>c</sup> and Kwok-Kong Tony Mong<sup>id\*ab</sup>

 Received 9th February 2021  
 Accepted 23rd February 2021

DOI: 10.1039/d1ra01088c

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

Herein, we report the total synthesis of landomycins Q and R as well as the aglycone core, namely anhydrolandomycinone and a related core analogue. The synthesis features an acetate-assisted arylation method for construction of the hindered B-ring in the core component and a one-pot aromatization–deiodination–denbenzylation procedure to streamline the global functional and protecting group manipulation. Subsequent cytotoxicity and antibacterial studies revealed that the landomycin R is a potential antibacterial agent against methicillin-resistant *Staphylococcus aureus*.

## Introduction

Over the past few decades, the emergence of multidrug-resistant nosocomial pathogens has become a worldwide issue that is of concern for scientists and clinical practitioners.<sup>1,2</sup> Consequently, new antibiotics and antibacterial strategies are urgently needed.<sup>3,4</sup> However, the development of a new antibiotic is a slow process that is associated with a high risk of failure. Compounds that exhibit antimicrobial capacity *in vitro* may be unable to combat the infection *in vivo* or may be highly toxic to the host cells.<sup>5</sup>

*Staphylococcus aureus* (*S. aureus*) is a class of Gram-positive bacteria that is present on the skin and mucous membranes as a part of normal flora.<sup>6</sup> If by chance *S. aureus* bacteria enter the bloodstream, they may cause severe infections including meningitides, endocarditis, and urinary tract infections.<sup>7</sup> Staphylococcal infections are common in community and hospital-acquired settings and treatment of these infections has been complicated because of the rising incidence of methicillin resistant *S. aureus* (MRSA) infections.<sup>8</sup> Although vancomycin is the antibiotic of choice, it may cause nephrotoxicity at high doses.<sup>9,10</sup> Therefore, a less or non-toxic antibiotic is desirable.<sup>11–13</sup>

The landomycins (LAs) are a class of angucyclines produced from *Streptomyces* species.<sup>14</sup> The first report on LA described the isolation of LA A to D from *S. cyanogenus* S136.<sup>15</sup> Through the use of the modern molecular biology techniques, the LA family has now grown to include more than 100 members.<sup>16,17</sup> The general structure of LA compounds comprises a tetracyclic core, which is substituted with some hydroxyl groups and a 2-deoxysaccharide chain at the C8 position (Fig. 1a).<sup>14–17</sup> Based on the B-ring structure and hydroxyl substitution pattern, four different core structures have been identified: tetrangulol, 5,6-anhydrolandomycinone, landomycinone, and 11-deoxylandomycinone. The combinations of different core structures and 2-deoxysaccharide chains provide a rich pool of natural products for structure and activity relationship studies.

Previous studies of LAs have mainly focused on the anti-cancer activity, and their potential antibacterial property has received far less attention.<sup>18</sup> Given that the demand for non-toxic antibiotics is on the rise, we sought to establish a versatile synthetic route to procure the anhydrolandomycinone core (1), the B-ring unsaturated core analogue (2), the LA Q (3), and LA R (4) for exploration of the cytotoxic and antibacterial properties (Fig. 1b).

## Results and discussion

### Synthesis of anhydrolandomycinone (1), B-ring unsaturated core analogue (2), LA Q (3), and LA R (4)

The total synthesis of LA A and LA D has been reported by Yu and Yang, but the synthesis of LA Q (3) and LA R (4) with a different core structure has not yet been realized.<sup>19</sup> From structural perspective, the synthesis of this class of compounds is non-trivial and yet challenging. Currently available protocols toward their aglycone core structure and glycone component

<sup>a</sup>National Chiao Tung University, Hsinchu 30010, Taiwan, Republic of China

<sup>b</sup>National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan, Republic of China. E-mail: [tmong@nycu.edu.tw](mailto:tmong@nycu.edu.tw)
<sup>c</sup>National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China

† Electronic supplementary information (ESI) available: Schemes S1 and S2 for preparation of 19, 20, and 22, Table S1 for comparison of NMR data, raw data of MTS, and MIC assays, experimental procedures, and NMR spectroscopic data and spectra were given. See DOI: 10.1039/d1ra01088c

‡ These authors contributed equally.







Fig. 1 (a) General Structure of LAs. (b) Structures of anhydrolandomycinone aglycone core (1), and B-ring unsaturated core analogue (2), LA R (3) and LA Q (4).

alone are inadequate for procurement of a complete LA scaffold.<sup>20,21</sup> Some modifications are required for selective removal of protecting groups and subsequent coupling reactions; but such modifications may not be tolerable to the original protocols. Thereby, we envisaged some synthetic challenges to realize the structures of our targets. These include: (i) the construction of a highly hindered B-ring; (ii) stereocontrol of the formation of the 2-deoxy- $\beta$ -glycosidic bonds; and (iii) the global deprotection in conditions tolerated by the rather fragile trideoxy- and dideoxy-glycosidic bonds (Fig. 1b).<sup>22</sup>

To tackle these challenges, new synthetic routes were designed, which was based on the modifications of literature protocols.<sup>19–21</sup> To access anhydrolandomycinone core (1) and its B-ring unsaturated analogue (2), the D-ring and A-ring building blocks 5 and 6 were prepared from available hydroquinone 7 and dimethylanisole 8, respectively. Based on the building blocks 5 and 6, the C and B-rings of the core scaffold were constructed.


In the preparation of the D-ring building block 5, regioselective acetylation of hydroquinone 7 with Zhang's procedure<sup>23</sup> followed by sequential benzylation and bromination gave the known 3-bromo-4-hydroxyphenyl acetate 9.<sup>24</sup> Then, 9 was converted to 1-(benzyloxy)-2-bromo-4-(methoxy-methoxy)-benzene 10 through deacetylation and methoxymethyl ether (MOM) protection (Scheme 1a). Subsequent lithiation of 10 in couple with Meerwein's salt methylation completed the preparation of building block 5 in 37% yield over seven steps.<sup>25</sup> Because of the poor stability of 5, it was freshly prepared prior to the Dötz benzannulation shown in Scheme 1c.



Scheme 1 Preparation of (a) D-ring building block 5, (b) A-ring alkyne building block 6, (c) anhydrolandomycinone (1), and corresponding B-ring unsaturated core analogue (2).

The preparation of the A-ring building block 6 started with readily available 3,5-dimethylanisole 8 (ref. 20b) instead of the more expensive 3-bromo-5-methylphenol as was the case in our previous synthesis.<sup>20d</sup> Thus, bromination of 3,5-dimethylanisole 8 with Wohl-Ziegler's procedure<sup>26</sup> followed by hydroxyl substitution afforded known (3-methoxy-5-methylphenyl)-methanol 11 (Scheme 1b).<sup>20b</sup> Subsequent directed-*ortho* lithiation of 11 and regioselective iodination gave (2-iodo-3-methoxy-5-methylphenyl)methanol 12 as the sole isomer.<sup>20b,27</sup> Acetylation of 12 followed by replacement of the methoxy group with benzyl ether protection provided 1-(benzyloxy)-3-(bromomethyl)-2-iodo-5-methylbenzene 13.<sup>20d</sup> Finally, the substitution of 13 with *in situ* prepared [3-TMS-prop-2-yn-1-yl] lithium and desilylation completed the preparation of building block 6 in 23% yield over eight steps.






Scheme 2 (a) Preparation of anhydrolandomycinone acceptor **18**. (b) Structures of L-rhodinosyl acetate **19** and olivosyl acetates **20**–**22**. (c) Preparation of D-olivosyl acetate **21**.

With the D- and A-ring building blocks **5** and **6** in hand, we embarked on the C-ring construction *via* Dötz benzannulation (Scheme 1c).<sup>28</sup> The annulation was followed by 2,3-dichloro-5,6-dicyano-benzoquinone (DDQ) oxidation to give the A-ring tethered naphthalene-1,4-dione **14**; which through Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> reduction and acetylation was converted to the A-ring tethered naphthalene-1,4-diacetate **15**. Subsequent acetate-assisted intramolecular directed arylation enabled construction of the B-ring in a highly congested environment.<sup>29</sup> The desired 5,6-

dihydropyrene-7,12-diyl-diacetate **16** was procured in a good 82% yield along with just a trace amount of the deiodination product of **15**. Removal of the acetyl groups of **16** followed by DDQ oxidation and acidic cleavage of the MOM protecting group gave 5,6-dihydropyrene-7,12-dione **17**. In subsequent hydrogenolytic debenzoylation, the modified RANEY®Ni catalyzed hydrogenation conditions were applied; whereas, the RANEY®Ni catalyst was freshly activated with NaOH(aq) and triethylamine (Et<sub>3</sub>N) was added as an acid scavenger.<sup>30</sup> Under the new conditions, no reduction of the carbonyl groups at C-ring occurred, while the B-ring was aromatized to give desired anhydrolandomycinone (**1**) in a one-pot fashion. In previous hydrogenation conditions, the carbonyl groups at the C-ring were also reduced, which had to be recovered by the DDQ oxidation.<sup>19,20d</sup> In addition to the synthesis of (**1**), removal of the benzyl protecting groups of **17** with BBr<sub>3</sub> furnished the B-ring unsaturated core analogue (**2**).

For the synthesis of LA **Q** (**3**) and **R** (**4**), partially protected anhydrolandomycinone **18** was initially employed as the aglycone acceptor, which could be derived from advanced intermediate **16** *via* four functional- and protecting-group manipulation steps (Scheme 2a). The 2-deoxytrisaccharide component of LA **Q** (**3**) was assembled from L-rhodinosyl acetates **19** (ref. 31) and, D-olivosyl acetates **20**,<sup>19a</sup> and **21**, while the 2-deoxy-disaccharide component of LA **R** (**4**) was built from the D-olivosyl acetates **21** and **22** (ref. 19a) (Scheme 2b). L-Rhodinosyl acetate **19** was derived from L-rhamnose (Scheme S1†), and D-olivosyl acetates **20** and **22** were derived from known glucal **23** according to literature procedures (Scheme S2†).<sup>32</sup> 6-Iodo-olivosyl acetate **21** was also prepared from **23** *via* intermediates **24** and **25** in 20% overall yield (Scheme 2c).



Scheme 3 (a) Preparation of anhydrolandomycinonyl β-olivoside acceptor **27**. (b) Preparation of disaccharide imidate donor **29**. (c) Total synthesis of LA **Q** (**3**).




In the construction of LA Q (3), an anhydrolandomycinonyl  $\beta$ -olivoside acceptor was prepared, which was subsequently coupled with a non-reducing-end disaccharide donor. In the preparation of the  $\beta$ -olivoside acceptor, 6-iodo-olivosyl acetate **21** was converted to an  $\alpha$ -olivosyl iodide by treatment with trimethylsilyl iodide (TMSI) (Scheme 3a).<sup>33</sup> After formation of the iodide intermediate, the DCM and residual TMSI were removed and the crude intermediate was reacted with the phenolate nucleophile, which was prepared *in situ* by deprotonation of **18** with potassium hexamethyldisilazane (KHMDs). Under the  $S_N2$  glycosylation conditions, the desired anhydrolandomycinonyl  $\beta$ -olivoside **26** was obtained in a satisfactory 68% yield with perfect selectivity. Assignment of the configuration of the *O*-aryl 2-deoxy- $\beta$ -glycosidic bond was supported by the  $^3J_{\text{H1-Hax}}$  coupling constant of 9.6 Hz. Notably, the above substitution occurred exclusively at C1 position despite the presence of the iodo substituent at the C6 position. Subsequent removal of the silyl protecting group afforded the desired  $\beta$ -olivoside acceptor **27** in 65% yield.

For the preparation of the disaccharide donor, olivosyl acetate acceptor **20** was coupled with rhodinoyl acetate donor

**19** to give  $\alpha$ -rhodinoyl-(1,3)-olivosyl acetate **28** (Scheme 3b). In the glycosylation, a low  $-60^\circ\text{C}$  temperature was applied to avoid the cleavage of the fragile 2,3,6-trideoxyglycosidic bond. Final replacement of the anomeric acetate group of **28** with *N*-phenyltrifluoroacetimidate completed the preparation of disaccharide imidate donor **29**.

The availability of donor **29** set the stage for the assembly of the target (Scheme 3c). Glycosylation of acceptor **27** with donor **29** gave protected LA Q **30** in a high 85% yield with excellent  $\beta$ -selectivity. The selectivity of the glycosylation is attributed to the participatory effect of the 2-iodo substituent group.<sup>34</sup> Subsequent one-pot deiodination and debenzoylation of **30** could be achieved under the same RANEY®Ni hydrogenation conditions as shown in Scheme 1c. Hydrolysis of the acyl protecting groups of the deiodinated and debenzoylated intermediate concluded the synthesis of LA Q (**3**) in 40% yield over two steps from **30**. The identity and structure of **3** were confirmed with HRMS and NMR spectroscopy. The proton chemical shifts of (**3**) were in full agreement with the data given from an authentic sample (Table S1†).<sup>16c</sup>



Scheme 4 (a) Preparation of B-ring unsaturated anhydrolandomycinonyl core acceptor **32**. (b) Total synthesis of LA R (**4**).

Table 1 Inhibitory effects on normal/cancer cell proliferation by anhydrolandomycinone (**1**), B-ring unsaturated core analogue (**2**), LA Q (**3**), and LA R (**4**)<sup>a</sup>

Entry	Compound	IC <sub>50</sub> (μM)		
		NCI-H460	SF-268	Detroit 551
1	Core ( <b>1</b> )	7.00 ± 0.70	8.57 ± 0.34	>10.0
2	B-ring unsaturated core ( <b>2</b> )	>10.0	>10.0	9.58 ± 0.66
3	LA Q ( <b>3</b> )	>10.0	>10.0	>10.0
4	LA R ( <b>4</b> )	>10.0	9.82 ± 0.08	>10.0

<sup>a</sup> Values represent the mean ± SD of three independent experiments.



Inspired by the one-pot debenzoylation and aromatization in Scheme 1c, and the one-pot debenzoylation and deiodination in Scheme 3c, we envisaged a simpler synthetic route for LA R (4), which would invoke a one-pot three-step, *i.e.* aromatization–debenzoylation–deiodination, procedure. With this aim, 5,6-dihydro-tetraphene-7,12-dione **17** in Scheme 1c was coupled with 6-iodo-olivosyl acetate **21** according to the above  $S_N2$ -glycosylation procedure to give 5,6-dihydro-tetraphene-7,12-dione  $\beta$ -olivoside **31** in 68% yield along with *ca.* 5% of the inseparable aromatization product **26** (Scheme 4a). The crude  $\beta$ -olivoside **31** was subjected to desilylation to give the 5,6-dihydro-tetraphene-7,12-dionyl  $\beta$ -olivoside acceptor **32** along with a small amount of olivoside **27**.

On the other hand, the non-reducing end olivosyl acetate **22** was converted to the trichloroacetimidate donor **33** by standard procedures (Scheme 4b). Subsequent glycosylation of  $\beta$ -olivoside acceptor **32** with donor **33** furnished 8-disaccharidyl-5,6-dihydro-tetraphene-7,12-dione **34** in 89% yield, though a tiny amount of glycosylation product arising from contaminant olivoside **27** was also produced. Without separation, the crude  $\beta$ -glycoside **34** was subjected to the one-pot aromatization–debenzoylation–deiodination procedure to afford a partially deprotected LA R intermediate in a satisfactory 55% yield. Final deprotection of the silyl and acetyl protecting groups concluded the total synthesis of LA R (4) in 74% yield over two steps.

### Exploration of the cytotoxic and antibacterial properties

Having acquired anhydrolandomycinone (1), the B-ring unsaturated core analogue (2), LA Q (3) and LA R (4), we evaluated their cytotoxicity with the [3-(dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium] (MTS) assay (Table 1).<sup>35,36</sup> Anhydrolandomycinone (1) was found to be cytotoxic against the cancer cell lines NCI-H460 and SF-268 with  $IC_{50}$  values at  $7.00 \pm 0.70$  and  $8.57 \pm 0.34$   $\mu$ M, respectively; but no appreciable cytotoxicity was noted for normal cell line Detroit 551 at 10  $\mu$ M (Entry 1). Intriguingly, such a toxicity pattern was reversed for the B-ring unsaturated core analogue (2) (Entry 2). At 10  $\mu$ M concentration of glycosylated LA Q (3) and R (4), no appreciable cytotoxic effect was detected for the normal cell line (Entries 3 and 4). Taken together, the unsaturated B ring and/or the 2-deoxysaccharide chain appear to play a role in the cytotoxicity of the LA compounds.

To elucidate the extent of the cytotoxicity, we evaluated the survival rates of Detroit 551 cell line at 10  $\mu$ M of the compounds, which were found to be  $59.00\% \pm 3.26\%$  for the core structure (1),  $104.2\% \pm 20.67\%$  for LA Q (3), and  $93.56\% \pm 10.02\%$  for LA

R (4), implicating that the anhydrolandomycinone alone is more toxic than its glycosylated products.

After clarifying the cytotoxicity profiles of 1–4, we examined the antibacterial activity with MRSA 4N 216 and 7Y001 (Table 2).<sup>37,38</sup> Among the compounds examined, only the disaccharide substituted LA R (4) exhibited inhibitory activity against MRSA 4N 216 and 7Y001 with the MIC values of 8 and 4  $\mu$ g mL<sup>-1</sup>, respectively. Although, such a potency is inferior to that offered by vancomycin (VA), the non-toxic nature of LA R (4) renders it a potential candidate for further optimization.

## Conclusion

In summary, a versatile strategy was established for the total synthesis of the anhydrolandomycinone core (1), the B-ring unsaturated anhydrolandomycinone analogue (2), landomycin Q (3), and landomycin R (4). The strategy employed the acetate-assisted intramolecular arylation for construction of the hindered B-ring of the anhydrolandomycin core and a one-pot aromatization, deiodination, and debenzoylation procedure was established to simplify the end-stage functional group manipulations. In subsequent MTS study, the structure of the B-ring and the degree of glycosylation of the landomycins appear to play a role in the cytotoxicity. Further exploration of the antibacterial properties revealed the potential of landomycin R (4) for inhibition of MRSA 4N 216 and 7Y001.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Thanks are given to the Ministry of Science and Technology in Taiwan (MOST) for financial support (grant no. MOST 109-2113-M-009-007).

## Notes and references

- (a) A. W. Robert, G. Robert and R. E. Jonathan, Overview of Nosocomial Infections Caused by Gram-Negative Bacilli, *Clin. Infect. Dis.*, 2005, **41**, 848–854; (b) F. Perez, A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather and R. A. Bonomo, Global challenge of multidrug-resistant *A. baumannii*, *Antimicrob. Agents Chemother.*, 2007, **51**, 3471–3484; (c) E. M. D'Agata, Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study, *Infect. Control Hosp. Epidemiol.*, 2004, **25**, 842–846.
- M. M. D'Andrea, M. Fraziano, M. C. Thaller and G. M. Rossolini, The Urgent Need for Novel Antimicrobial Agents and Strategies to Fight Antibiotic Resistance, *Antibiotics*, 2019, **8**, 254.
- I. Roca, *et al.*, The global threat of antimicrobial resistance: science for intervention, *New Microbes New Infect.*, 2015, **6**, 22–29.

**Table 2** *In vitro* inhibitory assay with anhydrolandomycinone (1), B-ring unsaturated core analogue (2), LA Q (3), and LA R (4)<sup>a</sup>

MRSA strain	MIC ( $\mu$ g mL <sup>-1</sup> ) of compound				
	Core (1)	Analogue (2)	LA Q (3)	LA R (4)	VA
4N216	>8	>8	>8	8	1
7Y001	>8	>8	>8	4	1

<sup>a</sup> Values are derived from two independent MIC experiments.



- 4 J. Bérdy, Thoughts and facts about antibiotics: where we are now and where we are heading, *J. Antibiot.*, 2012, **65**, 385–395.
- 5 (a) A. P. Tomaras, J. L. Crandon, C. J. McPherson, M. A. Banevicius, S. M. Finegan, R. L. Irvine, M. F. Brown, J. P. O'Donnell and D. P. Nicolau, Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by *Pseudomonas aeruginosa*, *Antimicrob. Agents Chemother.*, 2013, **57**, 4197–4207; (b) M. Ghosh, P. A. Miller, U. Möllmann, W. D. Claypool, V. A. Schroeder, W. R. Wolter, M. Suckow, H. Yu, S. Li, W. Huang, J. Zajicek and M. J. Miller, Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant *Acinetobacter baumannii* Both In Vitro and In Vivo, *J. Med. Chem.*, 2017, **60**, 4577–4583; (c) J.-K. Huang, T.-L. Yang, C.-C. Lin and K.-S. Shia, Total Synthesis of Tetarimycin A, ( $\pm$ )-Naphthacemycin A<sub>9</sub>, and ( $\pm$ )-Fasamycin A: Structure-Activity Relationship Studies against Drug-Resistant Bacteria, *J. Org. Chem.*, 2018, **83**(12), 6508–6523.
- 6 F. C. Henry, Community-Associated MRSA-Resistance and Virulence Converge, *N. Engl. J. Med.*, 2005, **352**, 1485–1487.
- 7 (a) F. D. Lowy, *Staphylococcus aureus* Infections, *N. Engl. J. Med.*, 1998, **339**, 520–532; (b) S. Y. Tong, J. S. Davis, E. Eichenberger, T. L. Holland and V. G. Fowler Jr, *Staphylococcus aureus* Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management, *Clin. Microbiol. Rev.*, 2015, **28**, 603–661.
- 8 H. W. Boucher and G. R. Corey, Epidemiology of Methicillin-Resistant *Staphylococcus aureus*, *Clin. Infect. Dis.*, 2008, **46**, S344–S349.
- 9 B. Oluwatoyin, Review of Vancomycin-Induced Renal Toxicity: An Update, *Ther. Adv. Endocrinol. Metab.*, 2016, **7**, 136–147.
- 10 S. W. Davies, C. A. Guidry, R. T. Petroze, T. Hranjec and R. G. Sawyer, Vancomycin and Nephrotoxicity: Just Another Myth?, *J. Trauma Acute Care Surg.*, 2013, **75**, 830–835.
- 11 R.-H. Song, B. Yu, D. Friedrich, J.-F. Li, H. Shen, H. Krautscheid, S.-D. Huang and M.-D. Kim, Naphthoquinone-derivative as a Synthetic Compound to Overcome the Antibiotic Resistance of Methicillin-resistant *Staph. aureus*, *Commun. Biol.*, 2020, **3**, 529.
- 12 J.-K. Huang, T.-L. Yang, C.-C. Lin and K.-S. Shia, Total Synthesis of Tetarimycin A, ( $\pm$ )-Naphthacemycin A<sub>9</sub>, and ( $\pm$ )-Fasamycin A: Structure-Activity Relationship Studies against Drug-Resistant Bacteria, *J. Org. Chem.*, 2018, **83**, 6508–6523.
- 13 H. Mohammad, N. S. Abutaleb and M. N. Seleem, Auranofin Rapidly Eradicates Methicillin-resistant *Staphylococcus aureus* (MRSA) in an Infected Pressure Ulcer Mouse Model, *Sci. Rep.*, 2020, **10**, 7251.
- 14 (a) M. K. Kharel, P. Pahari, M. D. Shepherd, N. Tibrewal, S. E. Nybo, K. A. Shaaban and J. Rohr, Angucyclines: biosynthesis, mode-of-action, new natural products, and synthesis, *Nat. Prod. Rep.*, 2012, **29**, 264–325; (b) B. Ostash, A. Korynevskaya, R. Stoika and V. Fedorenko, Chemistry and Biology of Landomycins, an Expanding Family of Polyketide Natural Products, *Mini-Rev. Med. Chem.*, 2009, **9**, 1040–1051.
- 15 T. Henkel, J. Rohr, J. Beale and L. Schwenen, Landomycins, new angucycline antibiotics from *Streptomyces* sp. I. Structural studies on Landomycins A-D, *J. Antibiot.*, 1990, **43**, 492–503.
- 16 (a) L. Zhu, A. Luzhetskyy, M. Luzhetskaya, C. Mattingly, V. Adams, A. Bechthold and J. Rohr, Generation of New Landomycins with Altered Saccharide Patterns through Over-expression of the Glycosyltransferase Gene lanGT3 in the Biosynthetic Gene Cluster of Landomycin A in *Streptomyces cyanogenus* S-136, *ChemBioChem*, 2007, **8**, 83–88; (b) B. Ostash, *et al.*, Generation of New Landomycins by Combinatorial Biosynthetic Manipulation of the LndGT4 Gene of the Landomycin E Cluster in *Strept. globisporus*, *Chem. Biol.*, 2004, **11**, 547–555; (c) K. A. Shaaban, S. Srinivasan, R. Kumar, C. Damodaran and J. Rohr, Landomycins P-W, Cytotoxic Angucyclines from *Streptomyces cyanogenus* S136, *J. Nat. Prod.*, 2011, **74**, 2–11.
- 17 K. A. Shaaban, C. Stamatkin, C. Damodaran and J. Rohr, 11-Deoxylandomycinone and landomycins X-Z, new cytotoxic angucyclin(on)es from a *Strept. cyanogenus* K62 mutant strain, *J. Antibiot.*, 2011, **64**, 141–150.
- 18 (a) R. Crow, B. Rosenbaum, R. Smith, Y. Guo, K. Ramos and G. Sulikowski, Landomycin A Inhibits DNA Synthesis and G1/S Cell Cycle Progression, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 1663–1666; (b) A. Korynevskaya, P. Heffeter, B. Matselyukh, L. Elbling, M. Micksche, R. Stoika and W. Berger, Mechanisms Underlying the Anti-cancer Activities of the Angucycline Landomycin E, *Biochem. Pharmacol.*, 2007, **74**, 1713–1726.
- 19 (a) X. Yang, B. Fu and B. Yu, Total Synthesis of Landomycin A, a Potent Antitumor Angucycline Antibiotic, *J. Am. Chem. Soc.*, 2011, **133**, 12433–12435; (b) X. Yang and B. Yu, Synthesis of landomycin D: studies on the saccharide assembly, *Synthesis*, 2016, **48**, 1693–1699.
- 20 Synthesis of anhydrolandomycinone aglycone: (a) D.-S. Hsu and J.-Y. Huang, Room-Temperature B(OAc)<sub>3</sub>-Promoted Diels–Alder Reaction of Juglone with Styrenes: Total Syntheses of Tetrangulol and Anhydrolandomycinone, *J. Org. Chem.*, 2012, **77**, 2659–2666; (b) S. Yamaguchi, H. Tanaka, R. Yamada, S. Kawauchi and T. Takahashi, Synthesis of a Landomycinone Skeleton via Masamune-Bergmann Cyclization, *RSC Adv.*, 2014, **4**, 32241–32248; (c) D. G. Vanga and K. P. Kaliappan, A Unified Strategy for the Syntheses of Angucyclinone Antibiotics: Total Syntheses of Tetrangulol, Kanglemycin M, X-14881-E, and Anhydrolandomycinone, *Eur. J. Org. Chem.*, 2012, 2250–2259; (d) C.-J. Sie, V. Patteti, Y.-R. Yang and T. K.-K. Mong, A General Strategy for Diverse Syntheses of Anhydrolandomycinone, Tetrangulol, and Landomycinone, *Chem. Commun.*, 2018, **54**, 1885–1888.
- 21 Synthesis of 2-deoxysaccharide fragments of LAs: (a) B. Yu and P. Wang, Efficient Synthesis of the Hexasaccharide Fragment of Landomycin A: Using Phenyl 2,3-O-Thionocarbonyl-1-thioglycosides as 2-Deoxy- $\beta$ -glycoside Precursors, *Org. Lett.*, 2002, **4**, 1919–1922; (b) M. Zhou and



- G. A. O'Doherty, Enantioselective Synthesis of 2-Deoxy- and 2,3-Dideoxyhexoses, *Org. Lett.*, 2008, **10**, 2283–2286; (c) H. Tanaka, S. Yamaguchi, A. Yoshizawa, M. Takagi, K. Shinya and T. Takahashi, Combinatorial Synthesis of Deoxyhexasaccharides Related to the Landomycin A Sugar Moiety, Based on an Orthogonal Deprotection Strategy, *Chem.-Asian J.*, 2010, **5**, 1407–1424; (d) D. Zhu, K. N. Baryal, S. Adhikari and J. Zhu, Direct Synthesis of 2-Deoxy- $\beta$ -Glycosides via Anomeric *O*-Alkylation with Secondary Electrophiles, *J. Am. Chem. Soc.*, 2014, **136**, 3172–3175; (e) J.-H. Ruei, P. Venukumar, A. B. Ingle and K.-K. T. Mong, C6 Picoloyl Protection: A Remote Stereodirecting Group for 2-Deoxy- $\beta$ -Glycoside Formation, *Chem. Commun.*, 2015, **51**, 5394–5397; (f) S. Yalamanchili, D. Lloyd and C. S. Bennett, Synthesis of the Hexasaccharide Fragment of Landomycin A Using a Mild, Reagent-Controlled Approach, *Org. Lett.*, 2019, **21**, 3674–3677.
- 22 X. Yang, P. Wang and B. Yu, Tackling the Challenges in the Total Synthesis of Landomycin A, *Chem. Rec.*, 2013, **13**, 70–84.
- 23 J.-C. Liu, J.-J. Fu, W.-L. Li, Y. Zou, Z.-J. Huang, J.-Y. Xu, S.-X. Peng and Y.-H. Zhang, Utilization of the Inherent Nucleophile for Regioselective *O*-Acylation of Polyphenols via an Intermolecular Cooperative Transesterification, *Tetrahedron Lett.*, 2016, **72**, 4103–4110.
- 24 For D-ring intermediate **9**: F. Falchi, S. M. Bertozzi, G. Ottonello, G. F. Ruda, G. Colombano, C. Fiorelli, C. Martucci, R. Bertorelli, R. Scarpelli, A. Cavalli, T. Bandiera and A. Armirotti, A New Kernel-Based, Partial Least Squares, QSRR Model for UPLC Retention Time Prediction: A Useful Tool for Metabolite Identification, *Anal. Chem.*, 2016, **88**, 9510–9517.
- 25 S. Pulley and B. Czako, Formal Total Synthesis of Shikonin via Dötz Benzannulation, *Tetrahedron Lett.*, 2004, **45**, 5511–5514.
- 26 A. Wohl, Bromination of Unsaturated Compounds with *N*-Bromosuccinimide, a Contribution to the Theory of the Course of Chemical Processes, *Eur. J. Inorg. Chem.*, 1919, 51–63.
- 27 V. Snieckus, Directed-*ortho* Metalation. Tertiary Amide and *O*-Carbamate Directors in Synthetic Strategies for Polysubstituted Aromatic, *Chem. Rev.*, 1990, **90**, 879–933.
- 28 (a) K. H. Dötz, Synthesis of the Naphthol Skeleton from Pentacarbonyl-[methoxy(phenyl)carbene]chromium (O) and To-lan, *Angew. Chem., Int. Ed.*, 1975, **14**, 644–645; (b) R. Fernandes and S. Mulay, Chiral Cups (Calixarenes) via Dötz Benzannulation, *Synthesis*, 2014, **46**, 1836–1846; (c) T. Bera, K. Pandey and R. Ali, The Dötz Benzannulation Reaction: A Booming Methodology for Natural Product Synthesis, *ChemistrySelect*, 2020, **5**, 5239–5267.
- 29 L.-C. Campeau, M. Parisien, A. Jean and K. Fagnou, Catalytic Direct Arylation with Aryl Chlorides, Bromides, and Iodides: Intramolecular Studies Leading to New Intermolecular Reactions, *J. Am. Chem. Soc.*, 2006, **128**, 581–590.
- 30 H. R. Billica and H. Adkins, Catalyst, Raney Nickel, W-6, *Org. Synth.*, 1949, **29**, 24 and references cited therein.
- 31 For building block **19**: O. Calin, R. Prangani and P. H. Seeberger, De Novo Synthesis of L-Colitose and L-Rhodinose Building Blocks, *J. Org. Chem.*, 2012, **77**, 870–877.
- 32 For glucal **23**: W. Roth and W. Pigman, D-Glucal and the Glycals. D-Glucal and 6-Deoxy-L-Dlucal, *Methods Carbohydr. Chem.*, 1963, 405–408.
- 33 S.-N. Lam and J. Gervay-Hague, Efficient Route to 2-Deoxy  $\beta$ -*O*-Aryl-D-glycosides via Direct Displacement of Glycosyl Iodides, *Org. Lett.*, 2003, **5**, 4219–4222.
- 34 W. R. Roush and C. E. Bennett, A Highly Stereoselective Synthesis of 2-Deoxy- $\beta$ -Glycosides using 2-Deoxy-2-Iodo-Glucopyranosyl Acetate Donors, *J. Am. Chem. Soc.*, 1999, **121**, 3541–3542.
- 35 C. J. Goodwin, S. J. Holt, S. Downes and N. J. Marshall, Microculture Tetrazolium Assays: a Comparison between Two New Tetrazolium Salts, XTT and MTS, *J. Immunol. Methods*, 1995, **179**, 95–103.
- 36 Promega, *CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay: Technical Bulletin No 169*, Promega Corporation, Madison, USA, 2001.
- 37 CLSI, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, CLSI standard M07, Clinical and Laboratory Standards Institute, Wayne, PA, 11th edn, 2018.
- 38 F.-J. Chen, T.-L. Lauderdale, C.-H. Lee, Y.-C. Hsu, I.-W. Huang, P.-C. Hsu and C.-S. Yang, Effect of a Point Mutation in *mprF* on Susceptibility to Daptomycin, Vancomycin, and Oxacillin in an MRSA Clinical Strain, *Front. Microbiol.*, 2018, **9**, 1086.

